New Aspects in Prostate Cancer Imaging

Dear Colleagues,

The usage and field of imaging in prostate cancer (PC) has developed tremendously over the last years, including significant advancements revolutionizing its detection, diagnosis and management. PC is one of the most prevalent malignancies affecting men worldwide; therefore, accurate imaging plays a crucial role in early detection and treatment planning.

Traditional imaging modalities, such as transrectal ultrasound and CT scans, have been limited in their ability to provide precise information about tumor location, size and aggressiveness. However, the advent of multiparametric magnetic resonance imaging (mpMRI) has emerged as a game-changer in PC diagnostics. mpMRI combines various sequences to visualize the prostate gland and surrounding tissues in unprecedented detail, enabling radiologists to identify suspicious lesions and guide targeted biopsies more accurately.

Additionally, the integration of positron emission tomography (PET) with novel radiotracers, such as prostate-specific membrane antigen (PSMA), has significantly improved PC primary staging and restaging. PSMA–PET offers unique sensitivity in detecting PC cells, even at low concentrations, helping clinicians assess disease spread and identify potential sites of metastases.

Furthermore, advancements in artificial intelligence and machine learning have facilitated the development of sophisticated image analysis algorithms, aiding in the automated interpretation of imaging data and providing clinicians with valuable insights for personalized treatment planning.

To summarize, the last decade has witnessed remarkable progress in PC imaging, with the introduction of mpMRI, PSMA–PET and AI-based analyses. These innovations have elevated the standard of care, enabling earlier detection, more accurate diagnosis and improved management of PC patients. As technology continues to evolve, the future holds great promise for further enhancing the efficacy of PC imaging and ultimately improving patient outcomes.

Original research articles and reviews are welcome for submission to this Special Issue. We look forward to receiving your contributions.

Dr. Bernhard Grubmüller
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.